Eur Heart J:非阻塞性冠状动脉和阻塞性冠状动脉心肌梗死患者结局比较

2019-06-21 xing.T 网络

由此可见,这项研究证实了接受冠状动脉造影的老年MINOCA患者的预后不良,五分之一的MINOCA患者在12个月内出现了严重的不良事件。

非阻塞性冠状动脉心肌梗死(MINOCA)患者的预后知之甚少。近日,心血管领域权威杂志Eur Heart J上发表了一篇研究文章,研究人员评估了MINOCA患者与冠状动脉疾病阻塞AMI患者(MICAD)的主要不良心脏事件(MACE),定义为全因死亡、急性心肌梗死(AMI)再次住院治疗、心力衰竭(HF)或AMI后12个月卒中

研究人员对来自国家心血管数据登记处CathPCI登记中心(2009年7月至2013年12月)的AMI患者(≥65岁)进行了多中心、观察性队列研究,这些患者接受了冠状动脉血管造影,并与医疗保险和医疗补助中心(CMS)的数据进行联系。根据存在或不存在≥50%狭窄的心外膜血管将患者分类为MICAD或MINOCA。该研究的主要终点是12个月时的MACE,次要终点包括超过12个月时MACE组成疾病。

在286780名AMI入院者中,16849名患者(5.9%)为MINOCA。MINOCA患者12个月的MACE率(18.7% vs. 27.6%)、死亡率(12.3% vs. 16.7%)和AMI再住院率(1.3% vs. 6.1%)和HF(5.9% vs. 9.3%)与MICAD患者相比显著降低(P<0.001),但MINOCA和MICAD患者卒中再次住院治疗相似(1.6% vs. 1.4%,P=0.128)。在进行风险调整后,与MICAD患者相比,MINOCA患者在12个月内的MACE风险降低43%(风险比=0.57,95%置信区间为0.55-0.59)。对于调整后的MACE各种组成疾病的风险,这种模式类似。

由此可见,这项研究证实了接受冠状动脉造影的老年MINOCA患者的预后不良,五分之一的MINOCA患者在12个月内出现了严重的不良事件。 

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1696890, encodeId=bd591696890f4, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Tue Nov 12 18:58:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357214, encodeId=a96a135e2140a, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 23 12:58:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480023, encodeId=dce2148002357, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Sun Jun 23 12:58:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563111, encodeId=e4cf1563111c9, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Jun 23 12:58:00 CST 2019, time=2019-06-23, status=1, ipAttribution=)]
    2019-11-12 tomyang96
  2. [GetPortalCommentsPageByObjectIdResponse(id=1696890, encodeId=bd591696890f4, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Tue Nov 12 18:58:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357214, encodeId=a96a135e2140a, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 23 12:58:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480023, encodeId=dce2148002357, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Sun Jun 23 12:58:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563111, encodeId=e4cf1563111c9, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Jun 23 12:58:00 CST 2019, time=2019-06-23, status=1, ipAttribution=)]
    2019-06-23 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1696890, encodeId=bd591696890f4, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Tue Nov 12 18:58:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357214, encodeId=a96a135e2140a, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 23 12:58:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480023, encodeId=dce2148002357, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Sun Jun 23 12:58:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563111, encodeId=e4cf1563111c9, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Jun 23 12:58:00 CST 2019, time=2019-06-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1696890, encodeId=bd591696890f4, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Tue Nov 12 18:58:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357214, encodeId=a96a135e2140a, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 23 12:58:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480023, encodeId=dce2148002357, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Sun Jun 23 12:58:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563111, encodeId=e4cf1563111c9, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Jun 23 12:58:00 CST 2019, time=2019-06-23, status=1, ipAttribution=)]
    2019-06-23 slcumt

相关资讯

Int J Cardiol:非阻塞性冠状动脉心肌梗死患者不良预后的预测因素!

由此可见,预测MINOCA患者新发MACE和死亡的临床因素与之前预测心肌梗死和阻塞性冠状动脉疾病患者心血管事件的因素惊人的相似。

Int J Cardiol:非阻塞性冠状动脉心肌梗死人群水平的发生率和结局分析!

由此可见,MINOCA人群水平的发病率约为5%。尽管他们的解剖发现是良性的,但必须努力改善二级预防策略,以减轻这一人群长期不良后果的负担。

Heart:无阻塞性冠状动脉心肌梗死患者结局分析

由此可见,MINOCA较为常见,其不良结局率约为阻塞性CAD患者的一半。死亡的主要原因是非CVD死亡。MINOCA患者的事件发生率明显高于没有CVD的人群。